In March 2024, the FDA approved the use of Resmetirom, a thyroid hormone receptor-β (THR-β) agonist, as the first and only medication for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (fibrosis stages F2 to F3) (44), in conjunction with healthy diet and exercise. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.